Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains

Brazilian Journal of Microbiology

Volumn 43, Issue 3, 2012, Pages 984-992

  Torres, Ieda Maria Sapateiro ^a   Bento, Etiene Barbosa ^a   Almeida, Larissa da Cunha ^a   de Sá, Luisa Zaiden Carvalho Martins ^a   Lima, Eliana Martins ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Cephalosporins; Liposomes; Pseudomonas aeruginosa

Indexed keywords

PSEUDOMONAS AERUGINOSA;

EID: 84870658099     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822012000300020     Document Type: Article

References (31)

1. Alipour M.; Halwani M.; Omri A.; Suntres Z.E. (2008). Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm. 355, 293-298.
2. Anderson M.; Omri A. (2004). The Effect of Different Lipid Componentes on the In Vitro Stability and Release Kinetics of Liposome Formulations. Drug Deliv. 11, 33-39.
3. o 1/2), 85-87.
4. Beaulac C.; Sachetelli S.; Lagace J. (1998). In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J Antimicrob Chemother. 41, 35-41.
5. Chastre J.; Trouillet J.L. (2000). Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect. 15, 287-298.
6. Clinical and Laboratory Standards Institute/NCCLS. (2005). Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15 [ISBN 1-56238-556-9]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
7. Drulis-Kawa Z.; Gubernator J.; Dorotkiewicz-Jach A.; Doroszkiewicz W.; Kozubek A. (2006). In vitro antimicrobial of liposomal meropenem against Pseudomonas aeruginosa strains. Int J Pharm. 315, 59-66.
8. Drulis-Kawa Z.; Dorotkiewicz-Jach A.; Gubernator J.; Gula G.; Bocer T.; Doroszkiewicz W. (2009). The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int. J Pharm. 367, 211-219.
9. Ellbogen M.H.; Olsen K.M.; Gentry-Nielsen M.J.; Preheim L.C. (2003). Efficacy of liposome encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in rat model of pneumococcal pneumonia. J. Antimicrob Chemother. 52, 83-91
10. Ferrara A.M. (2006). Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents. 27, 183-195.
11. Hancock R.E.W.; Speert D.P. (2000). Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat. 3, 247-255.
12. Hardman J.G.; Limbird L.E. (2001) Gilmans A.G. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill, New York.
13. Hauser A.R.; Sriram P. (2005). Severe Pseudomonas aeruginosa infections. Tackling the comundrum of drug resistance. Postgrad Med. 117 (1), 41-48.
14. Japoni A.; Alborzi A.; Kalani M.; Nasiri J.; Hayati M.; Farshad S. (2006). Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns. 32, 343-347.
15. Maurer N.; Wong K.F.; Hope M.J.; Cullis P.R. (1998). Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. Biochim Biophys Acta. 1374, 9-20.
16. McGowan J.E. (2006). Resistance in Nonfermenting Gram-Negative Bacteria: Multidrug Resistence to the Maximum. Am J Med. 119 (6A), S29-S36.
17. Mugabe C.; Azghani A.O.; Omri A. (2005). Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother. 55, 269-271.
18. Mugabe C.; Halwani M.; Azghani R.; Lafrenie R.M.; Omri A. (2006). Mechanism of enhanced Activity of Lipossome-Entrapped Aminoglycosides against Resistant Strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 50 (n° 6), 2016-2022.
19. Nacucchio M.C.; Bellora M.J.G.; Sordelli D.O.; D'Aquino M. (1985). Enhanced Liposome-Mediated Activity of Piperacillin Against Staphylococci. Antimicrob Agents Chemother. 27 (n°1), 137-139.
20. Nicolosi D.; Scalia M.; Nicolosi V.M.; Pignatello R. (2010). Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int J Antimicrob Agents. 35, 553-558.
21. Omri A.; Suntres Z.E.; Shek P.N. (2002). Enhanced activity of lipossomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol. 64, 1407-1413.
22. Omri A.; Ravaoarinoro M. (1996). Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int J Antimicrob Agents. 7, 9-14.
23. Park J.; Suh H.; Sung H.; Han D.; Lee D.H.; Park B.J.; Park Y.H.; Cho B.K. (2003). Liposomal Entrapment of Cefoxitin to Improve Cellular Viability and Function in Human Saphenous Veins. Artif Organs. 27 (7), 623-630.
24. Pfaller M.A.; Sader H.E.; Fritsche T.R.; Jones R.N. (2006). Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance program (1998-2004). Diagn Microbiol Infect Dis. 56, 63-68.
25. Rukholm G.; Mugabe C.; Azghani A.O.; Omri A. (2006). Antibacterial activity of lipossomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents. 27, 247-252.
26. Sachetelli S.; Beaulac C.; Riffon R.; Lagacé J. (1999). Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta. 1428, 334-340.
27. Sachetelli S.; Khalil H.; Chen T.; Beaulac C.; Senechal S.; Lagace J. (2000). Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta. 1463, 2554-2566.
28. Schiffelers R.; Storm G.; Bakker-Woudenberg I. (2001). Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother. 48, 333-344.
29. Sharma A.; Sharma U.S. (1997). Liposomes in drug delivery: progress and limitation. Int J Pharm. 154, 123-140.
30. Thomson J.M.; Bonomo R.A. (2005). The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril! Curr Opin Microbiol. 8, 518-524.
31. Vemuri S.; Rhodes C.T. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv. 70, 95-111.